Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study

2012 ◽  
Vol 48 (6) ◽  
pp. 813-819 ◽  
Author(s):  
Morten Brændengen ◽  
Kjell M. Tveit ◽  
Marianne J. Hjermstad ◽  
Hemming Johansson ◽  
Åke Berglund ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multimodal Treatment ◽  
Phase Iii ◽  
Long Term Results ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Phase Iii Study

M1512 Health Related Quality of Life and Clinical Outcome After Colonic Resection for Diverticular Disease: Long-Term Results

2008 ◽  
Vol 134 (4) ◽  
pp. A-863
Author(s):  
Marco Scarpa ◽  
Duilio Pagano ◽  
Cesare Ruffolo ◽  
Anna Pozza ◽  
Francesa Erroi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Outcome ◽  
Diverticular Disease ◽  
Colonic Resection ◽  
Long Term Results ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial

2007 ◽  
Vol 25 (36) ◽  
pp. 5723-5730 ◽  
Author(s):  
Martin J.B. Taphoorn ◽  
Martin J. van den Bent ◽  
Murielle E.L. Mauer ◽  
Corneel Coens ◽  
Jean-Yves Delattre ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Long Term Results ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
European Organisation ◽  
Related Quality ◽  
Health Related ◽  
Pcv Chemotherapy

Purpose Little is known about the health-related quality of life (HRQOL) of patients treated for anaplastic oligodendrogliomas. The impact of combined procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy after radiotherapy (RT) compared with RT alone on HRQOL in the randomized European Organisation for Research and Treatment of Cancer (EORTC) 26951 trial was studied. Patients and Methods Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy. HRQOL was assessed with the EORTC Quality of Life Questionnaire C30 and Brain Cancer Module. Seven prespecified HRQOL end points were selected. We hypothesized that chemotherapy would impair HRQOL during treatment but that there would be a similar HRQOL between treatment arms once off treatment. Assessments were performed at randomization, at the end of RT, and then every 3 to 6 months until progression. Results A total of 368 patients were randomly assigned to one of the two arms; overall, 58% were male, and the median age was 49 years. Compliance with HRQOL was 78% at baseline and dropped to 55% to 72% up to 2.5 years post-RT. Baseline scores demonstrated considerable impairments in HRQOL for both treatment groups. The longitudinal analysis showed a significant increase in nausea/vomiting in the RT plus PCV chemotherapy arm during and shortly after chemotherapy. Because of a difference in baseline scores for fatigue and physical functioning, the differences between treatment arms during PCV did not reach significance. The nonselected scales of appetite loss and drowsiness demonstrated significant differences between treatment arms during chemotherapy in favor of the RT arm. The long-term results showed no difference between arms. Conclusion The major impact of PCV on HRQOL is on nausea/vomiting, loss of appetite, and drowsiness during and shortly after treatment. There are no long-term effects of PCV chemotherapy.

scholarly journals P05.65 The caregiver burden in meningioma: long-term results and its effects on caregiver’s health-related quality of life, anxiety and depression

2018 ◽  
Vol 20 (suppl_3) ◽  
pp. iii318-iii318
Author(s):  
A H Zamanipoor Najafabadi ◽  
P B van der Meer ◽  
F W Boele ◽  
J C Reijneveld ◽  
M J B Taphoorn ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Caregiver Burden ◽  
Long Term Results ◽  
Anxiety And Depression ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document